Aceragen, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
505 Eagleview Boulevard, Suite 212, Exton, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
IDERA PHARMACEUTICALS, INC. (to 1/13/2023), HYBRIDON INC (to 9/2/2005)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 125 % -82.5%
Debt-to-equity 232 % +1197%
Return On Equity -215 % -211%
Return On Assets -53 % +9.74%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.42M shares -84.1%
Common Stock, Shares, Outstanding 8.35M shares -84.2%
Entity Public Float 24M USD -62.4%
Common Stock, Value, Issued 8K USD -84.9%
Weighted Average Number of Shares Outstanding, Basic 7.45M shares +139%
Weighted Average Number of Shares Outstanding, Diluted 7.45M shares +139%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15.4M USD +36.4%
General and Administrative Expense 14.7M USD +59.9%
Operating Income (Loss) -44.2M USD -103%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -22.1M USD -430%
Income Tax Expense (Benefit) -6.59M USD -205%
Net Income (Loss) Attributable to Parent -41M USD -88.1%
Earnings Per Share, Basic -8.78 USD/shares -130%
Earnings Per Share, Diluted -8.78 USD/shares +20%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.12M USD -92.4%
Cash, Cash Equivalents, and Short-term Investments 2.1M USD -92.5%
Accounts Receivable, after Allowance for Credit Loss, Current 2.2M USD
Assets, Current 5.64M USD -80.8%
Property, Plant and Equipment, Net 4K USD -77.8%
Operating Lease, Right-of-Use Asset 471K USD -31%
Intangible Assets, Net (Excluding Goodwill) 67M USD
Goodwill 4.63M USD
Assets 78.5M USD +160%
Accounts Payable, Current 3.41M USD +1320%
Accrued Liabilities, Current 7.2M USD +115%
Liabilities, Current 17.9M USD +371%
Deferred Income Tax Liabilities, Net 3.01M USD
Operating Lease, Liability, Noncurrent 271K USD -45.1%
Other Liabilities, Noncurrent 22K USD
Liabilities 55.9M USD +1204%
Accumulated Other Comprehensive Income (Loss), Net of Tax -23K USD
Retained Earnings (Accumulated Deficit) -781M USD -5.55%
Stockholders' Equity Attributable to Parent 22.5M USD -12.8%
Liabilities and Equity 78.5M USD +160%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.85M USD -116%
Net Cash Provided by (Used in) Financing Activities -74K USD -563%
Common Stock, Shares Authorized 140M shares 0%
Common Stock, Shares, Issued 8.35M shares -84.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.93M USD -118%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5K USD +66.7%
Deferred Tax Assets, Valuation Allowance 129M USD -3.4%
Deferred Tax Assets, Gross 141M USD +5.53%
Operating Lease, Liability 560K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.9M USD -423%
Lessee, Operating Lease, Liability, to be Paid 626K USD -25.5%
Property, Plant and Equipment, Gross 819K USD 0%
Operating Lease, Liability, Current 223K USD +4.21%
Lessee, Operating Lease, Liability, to be Paid, Year Two 240K USD -4%
Lessee, Operating Lease, Liability, to be Paid, Year One 285K USD +14.5%
Deferred Income Tax Expense (Benefit) -273K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 66K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 101K USD -57.9%
Deferred Tax Assets, Operating Loss Carryforwards 94.4M USD +4.2%
Preferred Stock, Shares Authorized 5M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 803M USD +4.94%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares